{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:24:14Z","timestamp":1767677054887},"reference-count":18,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CCID"],"DOI":"10.2147\/ccid.s444238","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T02:20:06Z","timestamp":1700187606000},"page":"3333-3339","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the Quality-of-Life Impact, Disease Burden, and Management Challenges of GPP: The Provider and Patient Perspective [Podcast]"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Jason E","family":"Hawkes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale","family":"Reisner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Bhutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1080\/1744666X.2022.2116003","volume":"18","author":"Bachelez","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jdv.18720","volume":"37","author":"Prinz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/PTT.S181808","volume":"9","author":"Ly","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"656104","DOI":"10.3389\/fpubh.2021.656104","volume":"9","author":"Tang","year":"2021","journal-title":"Front Public Health"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40257-021-00654-z","volume":"23","author":"Choon","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/00325481.2020.1831315","volume":"133","author":"Crowley","year":"2021","journal-title":"Postgrad Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40257-021-00664-x","volume":"23","author":"Zheng","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","volume":"23","author":"Krueger","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40257-021-00663-y","volume":"23","author":"Reisner","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s13555-021-00661-2","volume":"12","author":"Strober","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/PTT.S359011","volume":"12","author":"Lofvendahl","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"ref13","unstructured":"Boehringer Ingelheim. FDA approves the first treatment option for generalized pustular psoriasis flares in adults; 2022 Available from: https:\/\/www.boehringer-ingelheim.us\/press-release\/fda-approves-first-treatment-option-generalized-pustular-psoriasis-flares-adults. Accessed June 13, 2023."},{"key":"ref14","unstructured":"Boehringer Ingelheim. European Commission approves SPEVIGO\u00ae (spesolimab) for generalized pustular psoriasis flares; 2022. Available from: https:\/\/www.boehringer-ingelheim.com\/human-health\/skin-diseases\/gpp\/european-commission-approves-spevigo-spesolimab-generalized. Accessed June 13, 2023."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s13555-022-00835-6","volume":"13","author":"Morita","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0140-6736(23)01378-8","author":"Morita","year":"2023","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1080\/03007995.2021.1951192","volume":"37","author":"Hanna","year":"2021","journal-title":"Curr Med Res Opin"}],"container-title":["Clinical, Cosmetic and Investigational Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=94422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=94422","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T02:20:09Z","timestamp":1700187609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/exploring-the-quality-of-life-impact-disease-burden-and-management-cha-peer-reviewed-fulltext-article-CCID"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":18,"URL":"https:\/\/doi.org\/10.2147\/ccid.s444238","relation":{},"ISSN":["1178-7015"],"issn-type":[{"value":"1178-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}